An update on HPTN 083, the study that established that PrEP given as an injection every two months had superior efficacy to a daily pill in gay and bisexual men and transgender women, was presented this week at the Conference on Retroviruses and Opportunistic Infections (CROI 2022).
Injected PrEP: cabotegravir maintains its advantage over four years Read More »
♦ Single LEN SC doses up to 900 mg were generally safe and well tolerated – Injection-site reactions were common, but all were mild ♦ LEN 900 mg SC maintained target concentrations for 26 wk (6 mon), supporting its use as a q6mon antiretroviral agent ♦ PK simulations support LEN regimen with oral PK loading,
Lenacapavir Sustained Delivery Formulation Supports 6-Month Dosing Interval Read More »
This article describes the potential of GS-6207, a small molecule that disrupts the functions of HIV capsid protein, as a long-acting agent to treat or prevent infection with HIV.
Clinical targeting of HIV capsid protein with a long-acting small molecule Read More »
This study assess the terminal phase pharmacokinetics and safety of long-acting injectable cabotegravir in participants included in the HPTN 077 trial.
This is a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. Read More »
This is a phase 3, open-label, multicenter, noninferiority trial involving patients who had had plasma HIV-1 RNA levels of less than 50 copies per milliliter for at least 6 months while taking standard oral antiretroviral therapy. The primary end point was the percentage of participants with an HIV-1 RNA level of 50 copies per milliliter
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. Read More »
Long-acting injectable PrEP acceptability was high, especially at non-U.S. sites. Preferences for a LAI PrEP product compared to other methods was higher among males, many who were MSM, in the U.S., and higher among females in non-U.S. compared to U.S. sites, where both the need for new HIV prevention methods is greatest and contraceptive injectable
The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo.
In this Phase 1 study, single SC doses of LEN resulted in potent antiviral activity over 10 days ♦ Rare low-level resistance to LEN via a single mutation (Q67H) emerged only at LEN exposures below the expected exposure in Ph2/3 studies ♦ Previous in vitro characterization identified that Q67H mutation had the least impact on
Lenacapavir Resistance Analysis in a Phase 1b Clinical Proof-Of-Concept Study Read More »
This study evaluates the clinical evidence to date and efficacy and challenges of cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection in selected populations.
